| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S11892-006-0034-7 |
| P698 | PubMed publication ID | 16898571 |
| P2093 | author name string | Juris J Meier | |
| Michael A Nauck | |||
| P2860 | cites work | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 |
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes | Q28212600 | ||
| A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells | Q28567736 | ||
| Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans | Q33845996 | ||
| Preparation of highly active enterogastrone | Q34054149 | ||
| Pancreatic and intestinal processing of proglucagon in man. | Q34179390 | ||
| Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine | Q34180164 | ||
| Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus | Q34617065 | ||
| Exon duplication and divergence in the human preproglucagon gene | Q34713786 | ||
| Gastric inhibitory polypeptide: the neglected incretin revisited | Q34758871 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
| The incretin concept today | Q39227026 | ||
| On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane | Q39468517 | ||
| Immunoreactive gastric inhibitory polypeptide | Q39642179 | ||
| New developments in the incretin concept | Q39832287 | ||
| Gastric inhibitory polypeptide. | Q40083139 | ||
| Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
| Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance | Q40715144 | ||
| Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus | Q40772590 | ||
| Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man | Q40899849 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. | Q41710424 | ||
| Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. | Q42435174 | ||
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
| Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. | Q42503767 | ||
| Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations | Q42511153 | ||
| Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). | Q42574446 | ||
| To be or not to be--an incretin or enterogastrone? | Q42675447 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes | Q43778779 | ||
| GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion | Q43908148 | ||
| Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | Q44110180 | ||
| Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes | Q44467078 | ||
| Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects | Q44495085 | ||
| The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype | Q44616522 | ||
| Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects | Q44688781 | ||
| Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus | Q44765354 | ||
| Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance | Q44887107 | ||
| Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance | Q44953998 | ||
| Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes | Q45112803 | ||
| Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. | Q45161258 | ||
| Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus | Q46466735 | ||
| Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects | Q46570584 | ||
| Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. | Q46595558 | ||
| The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans | Q46887678 | ||
| Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients | Q47970570 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective | Q48335925 | ||
| Hamster preproglucagon contains the sequence of glucagon and two related peptides | Q48398917 | ||
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. | Q51244259 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. | Q51560034 | ||
| Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. | Q51567049 | ||
| Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. | Q51584065 | ||
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
| The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. | Q51619627 | ||
| A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence | Q53788072 | ||
| The pathogenesis of NIDDM involves a defective expression of the GIP receptor | Q58449027 | ||
| Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas* | Q58449399 | ||
| Identification of the intestinal cell storing gastric inhibitory peptide | Q66897947 | ||
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
| Disturbances of the entero-insular axis | Q70296199 | ||
| Glucose-dependent Insulinotropic Polypeptide Augmentation of Insulin Physiology or Pharmacology? | Q70332014 | ||
| Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 | Q77804907 | ||
| Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells | Q81118511 | ||
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses | Q93538767 | ||
| What are 'physiological' plasma GIP levels in man after intravenous infusion of porcine GIP? | Q93561788 | ||
| P433 | issue | 3 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 194-201 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Incretins and the development of type 2 diabetes | |
| P478 | volume | 6 |
| Q35838203 | A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers |
| Q26785454 | Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q37812853 | Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism |
| Q37949599 | Choosing a gliptin |
| Q46397532 | Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q58702412 | Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial |
| Q51318376 | Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. |
| Q36428062 | Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes |
| Q36755303 | Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes |
| Q91559415 | Function and mechanisms of enteroendocrine cells and gut hormones in metabolism |
| Q41965240 | GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. |
| Q39234083 | Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells |
| Q37015969 | Glucagon-like peptide-1 analogues: An overview |
| Q37175498 | Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus |
| Q39334553 | Insulin Resistance and Mitochondrial Dysfunction. |
| Q53687232 | Metabolic Syndrome and Neuroprotection. |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q37463887 | Pancreatic duct replication is increased with obesity and type 2 diabetes in humans |
| Q38005002 | Paracrine interactions within islets of Langerhans. |
| Q35832189 | Pharmacological management of metabolic syndrome and its lipid complications |
| Q35968092 | Pleiotropic effects of incretins |
| Q34070530 | Postprandial oxidative stress and gastrointestinal hormones: is there a link? |
| Q24628948 | Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes |
| Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
| Q43231241 | The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice |
| Q60301930 | Treatment approach to type 2 diabetes: Past, present and future |
Search more.